<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We explored the epidemiology of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in individuals with insulin-treated <z:mp ids='MP_0002055'>diabetes</z:mp> by testing the hypothesis that <z:mp ids='MP_0002055'>diabetes</z:mp> type and duration of insulin treatment influence the risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: This was an observational study over 9-12 months in six UK secondary care <z:mp ids='MP_0002055'>diabetes</z:mp> centres </plain></SENT>
<SENT sid="2" pm="."><plain>Altogether 383 patients were involved </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were divided into the following three treatment groups for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>: (1) <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>, (2) insulin for &lt;2 years and (3) insulin for &gt;5 years, and into two treatment groups for type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, namely &lt;5 years disease duration and &gt;15 years disease duration </plain></SENT>
<SENT sid="4" pm="."><plain>Self-reported (mild and severe) and biochemical episodes (interstitial <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;2.2 mmol/l using continuous <z:chebi fb="105" ids="17234">glucose</z:chebi> monitoring) were recorded </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Mild <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in type 2 diabetic patients on insulin for &lt;2 years was less frequent than in type 1 patients with &lt;5 years disease duration (mean rate: 4 vs 36 episodes per subject-year, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In type 2 diabetic patients treated with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> or insulin for &lt;2 years, no differences were observed in the proportion experiencing severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (7 vs 7%, difference 0 [95% CI: -7 to 9%]), mild symptomatic (39 vs 51%, difference 12 [-3 to 25%]) or interstitial <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;2.2 mol/l (22 vs 20%, difference 2 [-13 to 10%]) </plain></SENT>
<SENT sid="7" pm="."><plain>Severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> rates were comparable in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> or insulin &lt; 2 years (0.1 and 0.2 episodes per subject-year) and far less frequent than in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> (&lt;5 years group, 1.1; &gt;15 years group, 3.2.episodes per subject-year) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: During early insulin use in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the frequency of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> is generally equivalent to that observed in patients treated with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and considerably lower than during the first 5 years of treatment in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>